New Horizons in Fetal and Neonatal Alloimmune Thrombocytopenia

Abstract

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a common cause of severe thrombocytopenia in newborns. Intracranial bleeding may lead to severe neurological sequelae and mortality. Current management of pregnancies at risk is suboptimal. Prenatal FNAIT diagnosis commonly requires invasive procedures and therapy is associated with a high treatment burden. The present review explores advances in the field and their potential contribution to modification of the diagnostic and therapeutic landscape. Topics addressed include the role of noninvasive prenatal testing using fetal cell free DNA, insights into novel and prospective therapeutic options achieved through the development of murine models of FNAIT as well as the forecast for the progress in pregnancy risk stratification through advancement in the investigation of biological characteristics of alloantibodies and their association with the risk of fetal bleeding.

Keywords

bleeding - neonatal - pregnancy - thrombocytopenia - alloimmune - diagnosis

Publication History

Article published online:
11 November 2022

• References

• 1 Kamphuis MM, Paridaans NP, Porcelijn L, Lopriore E, Oepkes D. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics 2014; 133 (04) 715-721
• 2 Shulman NR, Aster RH, Pearson HA, Hiller MC. Immunoreactions involving platelet. VI. Reactions of maternal isoantibodies responsible for neonatal purpura. Differentiation of a second platelet antigen system. J Clin Invest 1962; 41: 1059-1069
• 3 Pearson HA, Shulman NR, Marder VJ, Cone Jr TE. Clinical and Therapeutic Considerations. Isoimmune neonatal thrombocytopenic purpura. Blood 1964; 23: 154-177
• 4 Bonstein L, Haddad N. Taking a wider view on fetal/neonatal alloimmune thrombocytopenia. Thromb Res 2017; 151 (suppl 1): S100-S102
• 5 Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol 2015; 171 (05) 671-682
• 6 Davoren A, Curtis BR, Aster RH, McFarland JG. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004; 44 (08) 1220-1225
• 7 Lee K, Godeau B, Fromont P. et al. CD36 deficiency is frequent and can cause platelet immunization in Africans. Transfusion 1999; 39 (08) 873-879
• 8 Ohto H, Miura S, Ariga H, Ishii T, Fujimori K, Morita S. Collaborative Study Group. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 2004; 14 (06) 399-408
• 9 Flesch BK, Scherer V, Opitz A. et al. Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness. Transfusion 2021; 61 (06) 1932-1942
• 10 Ma C, Wang J, Yang L. et al. A single-center investigational study of CD36 antigen deficiency and platelet alloantibody distribution in different populations in Northern China as well as platelet alloantibodies effect on pregnancy. Clin Chim Acta 2019; 498: 68-75
• 11 Delbos F, Bertrand G, Croisille L, Ansart-Pirenne H, Bierling P, Kaplan C. Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage. Transfusion 2016; 56 (01) 59-66 , quiz 58
• 12 Winkelhorst D, Kamphuis MM, de Kloet LC, Zwaginga JJ, Oepkes D, Lopriore E. Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literature. Transfusion 2016; 56 (05) 1230-1235
• 13 Overton TG, Duncan KR, Jolly M, Letsky E, Fisk NM. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002; 186 (04) 826-831
• 14 Bussel JB, Berkowitz RL, McFarland JG, Lynch L, Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319 (21) 1374-1378
• 15 Lieberman L, Greinacher A, Murphy MF. et al; International Collaboration for Transfusion Medicine Guidelines (ICTMG). Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol 2019; 185 (03) 549-562
• 16 Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2021; 225 (02) 120-127
• 17 Alfirevic Z, Navaratnam K, Mujezinovic F. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2017; 9: CD003252
• 18 Lo YM, Corbetta N, Chamberlain PF. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350 (9076): 485-487
• 19 Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn 2015; 35 (10) 972-979
• 20 Bianchi DW. Cherchez la femme: maternal incidental findings can explain discordant prenatal cell-free DNA sequencing results. Genet Med 2018; 20 (09) 910-917
• 21 Nogués N. Recent advances in non-invasive fetal HPA-1a typing. Transfus Apheresis Sci 2020; 59 (01) 102708
• 22 Orzińska A, Guz K, Uhrynowska M. et al. Noninvasive prenatal HPA-1 typing in HPA-1a negative pregnancies selected in the Polish PREVFNAIT screening program. Transfusion 2018; 58 (11) 2705-2711
• 23 Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008; 14 (05) 579-584
• 24 Wienzek-Lischka S, Krautwurst A, Fröhner V. et al. Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencing. Transfusion 2015; 55 (6 Pt 2): 1538-1544
• 25 Ouzegdouh Mammasse Y, Chenet C, Drubay D. et al. A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility. Br J Haematol 2020; 190 (05) 787-798
• 26 Sachs UJ. Prospects for risk stratification of anti-HPA-1a alloimmunized pregnant women. Transfus Apheresis Sci 2020; 59 (01) 102709
• 27 Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008; 93 (06) 870-877
• 28 Kjaer M, Bertrand G, Bakchoul T. et al; International Collaboration for Transfusion Medicine Guidelines. Maternal HPA-1a antibody level and its role in predicting the severity of fetal/neonatal alloimmune thrombocytopenia: a systematic review. Vox Sang 2019; 114 (01) 79-94
• 29 Ahlen MT, Husebekk A, Killie MK, Skogen B, Stuge TB. T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells. Blood 2009; 113 (16) 3838-3844
• 30 Kjeldsen-Kragh J, Bengtsson J. Fetal and neonatal alloimmune thrombocytopenia-new prospects for fetal risk assessment of HPA-1a-negative pregnant women. Transfus Med Rev 2020; 34 (04) 270-276
• 31 Yougbaré I, Lang S, Yang H. et al. Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest 2015; 125 (04) 1545-1556
• 32 Dardik R, Salomon O. Maternal Anti-HPA-1a Antibodies Increase Endothelial Cell Apoptosis and Permeability. J Vasc Res 2021; 58 (05) 321-329
• 33 Santoso S, Wihadmadyatami H, Bakchoul T. et al. Antiendothelial αvβ3 antibodies are a major cause of intracranial bleeding in fetal/neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol 2016; 36 (08) 1517-1524
• 34 Kapur R, Kustiawan I, Vestrheim A. et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 2014; 123 (04) 471-480
• 35 Sonneveld ME, Natunen S, Sainio S. et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol 2016; 174 (02) 310-320
• 36 Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol 2018; 9: 1299
• 37 Daniel GW, Menis M, Sridhar G. et al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion 2012; 52 (10) 2113-2121
• 38 Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359 (19) 2025-2033
• 39 Rossi KQ, Lehman KJ, O'Shaughnessy RW. Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. J Matern Fetal Neonatal Med 2016; 29 (11) 1783-1788
• 40 Tiller H, Ahlen MT, Akkök CA, Husebekk A. Fetal and neonatal alloimmune thrombocytopenia - the Norwegian management model. Transfus Apheresis Sci 2020; 59 (01) 102711
• 41 Ernstsen SL, Ahlen MT, Johansen T, Bertelsen EL, Kjeldsen-Kragh J, Tiller H. Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia: comparison of neonatal outcome in treated and nontreated pregnancies. Am J Obstet Gynecol 2022; 227 (03) 506.e1-506.e12
• 42 Ni H, Chen P, Spring CM. et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006; 107 (07) 2976-2983
• 43 Barg AA, Hauschner H, Luboshitz J. et al. From thrombasthenia to next generation thrombocytopenia: Neonatal alloimmune thrombocytopenia induced by maternal Glanzmann thrombasthenia. Pediatr Blood Cancer 2018; 65 (12) e27376
• 44 Zhi H, Ahlen MT, Skogen B, Newman DK, Newman PJ. Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia. Blood Adv 2021; 5 (18) 3552-3562
• 45 Mørtberg TV, Zhi H, Vidarsson G. et al. Prevention of fetal/neonatal alloimmune thrombocytopenia in mice: biochemical and cell biological characterization of isoforms of a human monoclonal antibody. Immunohorizons 2022; 6 (01) 90-103
• 46 Wu Y, Chen D, Xu X. et al. Hydrops fetalis associated with anti-CD36 antibodies in fetal and neonatal alloimmune thrombocytopenia: possible underlying mechanism. Transfus Med 2020; 30 (05) 361-368
• 47 Xu X, Chen D, Ye X. et al. Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model. Blood 2021; 138 (18) 1757-1767
• 48 Qureshi H, Massey E, Kirwan D. et al; British Society for Haematology. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014; 24 (01) 8-20
• 49 Kjeldsen-Kragh J, Killie MK, Tomter G. et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110 (03) 833-839
• 50 Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007; 114 (05) 588-595
• 51 Winkelhorst D, Loeff RM, van den Akker-Van Marle ME, de Haas M, Oepkes D. Women's attitude towards routine human platelet antigen-screening in pregnancy. Acta Obstet Gynecol Scand 2017; 96 (08) 991-997
• 52 Kjeldsen-Kragh J, Titze TL, Lie BA, Vaage JT, Kjær M. HLA-DRB3*01:01 exhibits a dose-dependent impact on HPA-1a antibody levels in HPA-1a-immunized women. Blood Adv 2019; 3 (07) 945-951
• 53 de Vos TW, Porcelijn L, Hofstede-van Egmond S. et al. Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia. Br J Haematol 2021; 195 (04) 595-603
• 54 Alm J, Duong Y, Wienzek-Lischka S. et al. Anti-human platelet antigen-5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?. Br J Haematol 2022; 198 (01) 14-23
• 55 Curtis BR. Are HPA-5b antibodies a significant cause of FNAIT and associated bleeding or merely an incidental finding?. Br J Haematol 2021; 195 (04) 485-486